

SUBJECT INDEX

- ABIOMED AB5000 ventricle, intraoperative off-bypass management of, 76–78
- Acetaminophen
intravenous, for postoperative pain, in CABG surgery, 306–309
with thoracic epidural anesthesia, for thoracotomy, 475–478
- Acid-base management, at body temperature extremes, fentanyl pKa and, 759–762
- Activated partial thromboplastin time, volume expander effects on, 358–361
- Acute respiratory distress, transesophageal echocardiography in, 242–249
- Adenosine, for myocardial protection, in off-pump CABG surgery, 672
- Afibrinogenemia, cardiac surgery in, 109–117
- Air embolism, ventricular, after cardiac surgery, 406–408
- Airway
foreign body removal from, in pediatric patients, 90–92
obstruction of
cystic mediastinal mass aspiration for, 781–784
in jugular venous puncture, 659–660
off-pump CABG surgery with subtotal thyroidectomy in, 79–82
- Albuminuria, after cardiopulmonary bypass, 188–192
- Analgesia, postoperative. *See* Postoperative pain
- Anesthesia
epidural. *See* Epidural anesthesia
fast-track. *See* Fast-track anesthesia
general, for CABG surgery
fast-track, 49–53
off-pump, 32–38
- Aneurysm
aortic, repair of
cerebrospinal fluid drainage during, 392–399
diastolic function during, 165–172
retrograde cerebral perfusion during, 650–653
atrial septal, transesophageal echocardiography in, 146–149, 529–538
endovascular repair of, anesthesiologist needed for
evidence against, 806–809
evidence for, 802–805
- Angioplasty
carotid, with stenting, for stroke prevention, 539–541
coronary, cardiopulmonary bypass for, 501–504
- Angiotensin-converting enzyme inhibitors, for diastolic dysfunction, in elderly persons, 231–234
- Animal studies
inflammatory response in cardiopulmonary bypass, 488–493
myocardial calcium cycling, 340–344
- Anticoagulants, preoperative, risk/benefit of, 1–3, 768–771
- Antifibrinolytic agents, for thoracic aortic surgery, 453–458
- Aorta
aneurysm of, repair of
cerebrospinal fluid drainage during, 392–399
diastolic function during, 165–172
endovascular, anesthesiologist needed for, 802–805, 806–809
retrograde cerebral perfusion during, 650–653
cross-clamping of
in aneurysm repair, diastolic function and, 165–172
release of, pacing electrocardiography after, 810–811
dissection of, paroxysmal sympathetic storms after, 654–655
surgery on
antifibrinolytic use in, 453–458
with deep hypothermic circulatory arrest, outcomes of, 446–452
sepsis after, immunoglobulins for, 440–445
- Aortic valve
graft for, thrombosis of, in pregnancy, 222–224
- Aortic valve (*Continued*)
prosthetic, intra-annular leak of, 691–692
regurgitation of, after left ventricular assist device placement, 409–410
replacement of, autologous transfusions for, 589–596
stenosis of, with patent ductus arteriosus, 785–786
surgery on, vs. analgesia type, 176–181
- Apolipoprotein E, in cardiac surgery, polymorphisms of, 382, 385
- Arterial switch operations, outcome of, 322–328
- Arteries. *See specific arteries*
- Aspiration, of cystic mediastinal mass, for airway compression, 781–784
- Atrial fibrillation
in CABG surgery, magnesium supplementation for, 723–729
after cardiac surgery, in elderly persons, 182–187
in cardiac surgery, genetic factors in, 384
after deep hypothermic circulatory arrest, for thoracic aortic surgery, 446–452
- Atrial muscle, contractility of, remifentanyl effects on, 763–767
- Atrial myxoma, infection of, septic shock in, 508–511
- Atrial septal aneurysm, transesophageal echocardiography in, 146–149, 529–538
- Atrial septal defects, closure of
autologous transfusions for, 589–596
cardiopulmonary bypass in, in moyamoya disease, 499–500
mini-extracorporeal circulation for, 656–658
- Atrioventricular block, complete, pacemaker implantation for, in pediatric patients, 212–216
- Atrium, coronary artery fistula with, transesophageal echocardiography in, 777–780
- Axillary artery, cannulation of, for cardiopulmonary bypass, blood pressure monitoring in, 665–666
- Bacteremia, after CABG surgery, transfusions and, 430–434
- Balloon, intra-aortic. *See* Intra-aortic balloon counterpulsation
- Barter's syndrome, cardiac surgery in, 373–376
- Beta-blockers
perioperative, late outcomes and, 237–241
for vascular surgery with positive preoperative stress tests, 494–498
- Bispectral index, for isoflurane monitoring, in cardiopulmonary bypass, 485–487
- Bleeding
in afibrinogenemia, cardiac surgery in, 109–117
gastrointestinal, in transesophageal echocardiography, 141–146
in mediastinoscopy, 678–683
risk of, postoperative
anticoagulant decisions and, 1–3
enoxaparin-induced, 4–10
subarachnoid, in aortic aneurysm repair, 650–653
- Blood loss, in cardiopulmonary bypass, hemostatic factors levels and, 459–467
- Blood pressure monitoring
after cardiac surgery, methods for, 746–750
in cardiopulmonary bypass, with axillary artery cannulation, 665–666
- Blood transfusions. *See* Transfusion(s)
- Body temperature, vs. fentanyl pKa, 759–762
- Brachial artery catheter, for cardiac output monitoring, in off-pump CABG surgery, 160–164
- Brain, retrograde perfusion of, in aortic aneurysm repair, 650–653
- Bronchoscopy
in foreign body removal, 90–92
laser treatment with
in bronchoscopy suite, 118–120
in operating room, 121–122

- CABG surgery. *See* Coronary artery bypass graft (CABG) surgery
- Calcium channel blockers, for myocardial protection, in off-pump CABG surgery, 670
- Calcium cycling, in myocardium, anesthesia effects on, 340–344
- Capillary permeability, after cardiopulmonary bypass, 188–192
- Cardiac catheterization, EMLA cream for, in pediatric patients, 642–645
- Cardiac index, normobaric hyperoxia effects on, after CABG surgery, 173–175
- Cardiac output, monitoring of
 after cardiac surgery, methods for, 746–750
 in off-pump CABG surgery, 160–164
- Cardiac surgery. *See also specific procedures*
 caudal anesthesia for, in pediatric patients, 734–738
 chest tube removal after, topical analgesia for, 719–722
 defibrillation methods for, 738–745
 hemodynamic measurements after, 746–750
 pericardial tamponade after, electrocardiography in, 775–776
 preoperative hepatic venous flow measurement in, 751–758
 ventricular fibrillation in, defibrillation methods for, 738–745
- Cardiac tamponade
 after cardiac surgery, electrocardiography in, 775–776
 intraoperative, in liver transplantation, rescue echocardiography in, 364–366
- Cardiogenic shock, 97–108
 after CABG surgery, echocardiographic-assisted management of, 772–774
 diagnosis of, 97
 etiology of, 98
 hemodynamic changes in, 97–98
 systemic inflammatory response syndrome and, 98
 transesophageal echocardiography in, 406–408
 treatment of, 98–105
 intra-aortic balloon counterpulsation in, 98–99
 pharmacologic, 99–105
 primary, 98
- Cardioprotection, sodium hydrogen ion exchange inhibitors for, 565–569, 570–576
- Cardiopulmonary bypass
 blood pressure monitoring in, in axillary artery cannulation, 665–666
 capillary leak after, 188–192
 cognitive dysfunction after, statins for, 294–298
 fentanyl concentrations in, in pediatric patients, 316–321
 glucose control during, 201–208
 hemostatic factors levels during, 459–467
 heparin-bonded circuits for, 608–611
 hyperthermia after, 423–425, 426–429
 infections after, transfusions and, 430–434
 inflammatory response in, xenon effects on, 488–493
 isoflurane requirements in, monitoring of, with bispectral index, 485–487
 laboratory value perturbations after, 19–25
 left ventricular relaxation after, milrinone vs. epinephrine for, 334–339
 length of stay after, vs. off-pump CABG surgery, 26–31
 normothermic, in moyamoya disease, 499–500
 for percutaneous coronary interventions, 501–504
 phenoxybenzamine vs. sodium nitroprusside for, in pediatric patients, 54–59
 with thoracic epidural anesthesia, 300–305
 weaning from, levosimendan for, 345–349
- Carotid artery disease, stroke prevention in
 carotid angioplasty and stenting for, 539–541
 endarterectomy for, 542–545
- Catecholamines, for cardiogenic shock, 99–101
- Catheter(ization)
 cardiac, EMLA cream for, in pediatric patients, 642–645
 intrapleural, for postoperative analgesia, 261–262
 pulmonary artery
 for hemodynamic measurements, after cardiac surgery, 746–750
 kinking of, in robotic surgery, 548–550
 Caudal anesthesia, for cardiac surgery, in pediatric patients, 734–738
- Central venous catheter, tension hydrothorax from, 512–515
- Central venous pressure, monitoring of, after cardiac surgery, methods for, 746–750
- Cerebrospinal fluid drainage, in aortic aneurysm repair, 392–399
- Charles Bonnet syndrome, after CABG surgery, 217–219
- Chest tube removal, topical analgesia for, 719–722
- Cisatracurium, for fast-track CABG surgery, 49–53
- Clonidine, for fast-track CABG surgery, 49–53
- Coagulation disorders
 in afibrinogenemia, cardiac surgery in, 109–117
 in CABG surgery, with cardiopulmonary bypass, 19–25
 in cardiac surgery, genetic factors in, 385–386
 in Sneddon syndrome, mitral valve replacement in, 661–664
 volume expanders and, 358–361
- Codeine, for postoperative pain, in CABG surgery, 714–718
- Cognitive dysfunction
 in cardiac surgery, genetic factors in, 384–385
 after cardiopulmonary bypass, statins for, 294–298
- Congenital heart defects, repair of
 caudal anesthesia for, 734–738
 combined aortic stenosis and patent ductus arteriosus, 785–786
 complex arterial switch, 322–328
 fentanyl for, 316–321
 Fontan procedure in, 612–619
 ketamine for, 329–333
 phenoxybenzamine vs. sodium nitroprusside for, 54–59
 Port-Access in, 626–629
 subglottic stenosis after, 367–369
 with β -thalassemia major, 93–96
 troponin I assay in, in neonates, 620–625
- Coronary angioplasty, cardiopulmonary bypass for, 501–504
- Coronary artery(ies), fistula of, transesophageal echocardiography in, 777–780
- Coronary artery bypass graft (CABG) surgery
 atrial fibrillation after, in elderly persons, 182–187
 autologous transfusions for, 589–596
 in Bartter's syndrome, 373–376
 beta-blockers for, late outcomes and, 237–241
 capillary leak after, 188–192
 cardiogenic shock after, echocardiographic-assisted management of, 772–774
 cognitive dysfunction after, statins for, 294–298
 complications of, in elderly persons, 583–588
 defibrillation in, biphasic vs. monophasic, 738–745
 desflurane-fentanyl for, 597–602
 fentanyl for
 with desflurane, 597–602
 hemodynamic effects of, 197–200
 with midazolam, 597–602
 glucose control during, 201–208
 grafts for, stellate ganglion blockade effects on, 729–733
 hemodynamic measurements after, 746–750
 heparin-bonded circuits for, 608–611
 infections after, 430–434
 laboratory value perturbations after, 19–25

- Coronary artery bypass graft (CABG) surgery (*Continued*)
 left ventricular relaxation after, milrinone vs. epinephrine for, 334–339
 length of stay after, 26–31
 midazolam-fentanyl for, 597–602
 minimally-invasive, intrathecal morphine for, 40–43
 myocardial ischemia after, troponin I assay in, 288–293
 normobaric hyperoxia in, cardiac index reduction in, 173–175
 off-pump
 anesthesia techniques for, 32–38
 atrial fibrillation in, magnesium supplementation for, 723–729
 cardiac output monitoring in, 160–164
 hemodynamic measurements after, 746–750
 hepatocellular damage attenuation by, 603–607
 hyperthermia after, 423–425, 426–429
 immediate extubation after, 282–287
 length of stay after, 26–31
 morphine for, 708–713
 myocardial ischemia in, reduction of, 667–677
 neurologic disorders after, 193–196
 remifentanyl for, 708–713
 resource utilization in, in elderly persons, 583–588
 subtotal thyroidectomy with, 79–82
 vein graft patency after, 11–18
 patent foramen ovale diagnosis during, 150–154
 postoperative pain in
 acetaminophen for, 306–309
 magnesium sulfate for, 714–718
 morphine for, 708–713
 NSAIDs for, 714–718
 opioids for, 714–718
 remifentanyl for, 708–713
 preoperative anticoagulants for, risk/benefit of, 1–3, 4–10
 preoperative hepatic venous flow measurement in, 751–758
 resource utilization in, in elderly persons, 583–588
 sepsis after, immunoglobulins for, 440–445
 thoracic epidural anesthesia for, prospective audit of, 44–48
 visual hallucinations after, 217–219
 Corticosteroids, for cardiopulmonary bypass
 evidence against, 255–258
 evidence for, 242–249
 Cystic fibrosis, double-lung transplantation in, pulmonary vein thrombosis
 in, 225–227
 Cytokines, in cardiac surgery, polymorphisms of, 381–384
- Deep hypothermic circulatory arrest, for thoracic aortic surgery, out-
 comes of, 446–452
 Defibrillation, for cardiac surgery, biphasic vs. monophasic, 738–745
 Delirium, after deep hypothermic circulatory arrest, for thoracic aortic
 surgery, 446–452
 Desflurane, for CABG surgery, 597–602
 Dexmedetomidine, for postoperative pain, in thoracotomy, 630–635
 Diabetes mellitus, glucose control in, during cardiac surgery, 201–208
 Diastolic dysfunction, in elderly persons, 228–236
 clinical implications of, 230–231
 diagnosis of, 230
 management of, 231–234
 pathophysiology of, 228–230
 physiology of, 228
 Diastolic function, in aortic aneurysm repair, aortic cross-clamping and,
 165–172
 Diclofenac, for postoperative pain, in CABG surgery, 714–718
 Diphasic defibrillation, for cardiac surgery, 738–745
 Dissection, aortic, paroxysmal sympathetic storms after, 654–655
- Dobutamine
 for cardiogenic shock, 100–101
 for stress echocardiography, in risk assessment, 520–528
 Dopamine, for cardiogenic shock, 100–101
 Dopexamine, for cardiogenic shock, 100–101
 Doppler studies
 of arterial grafts, in stellate ganglion block, 729–733
 in hemodynamic monitoring, after cardiac surgery, 746–750
 in hepatic venous flow, before cardiac surgery, 751–758
 in interatrial septum, 146–149
 in left ventricular relaxation, after cardiopulmonary bypass, 334–339
 in preoperative hepatic venous flow measurement in, 751–758
 Double arterial switch, outcome of, 322–328
 Dysphagia lusoria, due to right aberrant subclavian artery, 86–89
- Echocardiography
 dobutamine stress, in risk assessment, 520–528
 transesophageal. *See* Transesophageal echocardiography
 transgastric, artifacts in, with papillary anomaly, 126–127
 transthoracic, portable device for, 155–159
 Editorials
 hyperthermia after cardiac surgery, 423–425
 immediate extubation in off-pump CABG surgery, 279–281
 intraoperative transesophageal echocardiography, 139
 postoperative pain in cardiac surgery, 705–707
 preoperative anticoagulant risk/benefit, 1
 sodium hydrogen ion exchange inhibitors, 565–569
 Elderly persons
 atrial fibrillation in, after cardiac surgery, 182–187
 CABG in, resource utilization and, 583–588
 diastolic dysfunction in, review of, 228–236
 Electrocardiography, after aortic cross-clamp release, 810–811
 Embolism, air, ventricular, after cardiac surgery, 406–408
 EMLA cream, for cardiac catheterization, in pediatric patients, 642–645
 Emphysema, one-lung ventilation in, arterial oxygen pressure, 479–484
 Endarterectomy, carotid, for stroke prevention, 542–545
 Endocarditis
 infectious, surgery for, outcome of, 435–439
 marantic, surgery for, in afibrinogenemia, 109–117
 transesophageal echocardiography in, 646–649
 tricuspid valve, with pacemaker infection, 505–507
 Endotracheal intubation, selective left bronchial, in pediatric patients,
 636–641
 Endovascular repair, anesthesiologist needed for
 evidence against, 806–809
 evidence for, 802–805
 Enoxaparin, preoperative, risk/benefit of, 4–10
 Epidural anesthesia
 lumbar, for post-thoracotomy pain, 468–474
 thoracic
 for aortic valve surgery, extubation after, 176–181
 for CABG surgery, off-pump, 32–38
 for cardiac surgery
 with cardiopulmonary bypass, 300–305
 prospective audit of, 44–48
 for esophagectomy, 350–357
 for mitral valve surgery, anticoagulation and, 768–771
 for thoracotomy, 630–635
 acetaminophen with, 475–478
 for postoperative pain, 787–794
 Epinephrine
 for cardiogenic shock, 100–101
 left ventricular relaxation effects of, after cardiopulmonary bypass,
 334–339

- Errata, incorrect departmental affiliations in Vol. 19, No. 3, page 350, 563
- Esophagectomy, postoperative analgesia for, 350–357
- Esophagus
injury of, in transesophageal echocardiography, 141–146
stricture of, transesophageal echocardiography in, 209–211
- Etomidate, for CABG surgery, fast-track, 49–53
- Extracorporeal circulation, with closed system, for atrial septal defect closure, 656–658
- Extubation, timing of
after aortic valve surgery, vs. analgesia type, 176–181
after off-pump CABG surgery, 282–287
after pediatric cardiac surgery, caudal anesthesia and, 734–738
- Factor V Leiden, thrombosis in, 385
- Fast-track anesthesia
for aortic valve surgery, vs. analgesia type, 176–181
for CABG surgery
 general with spinal, 49–53
 length of stay and, 26–31
 minimally invasive, 40–43
- Femoral artery, cannulation of, in pediatric patients, 642–645
- Femoral nerve block, with sciatic nerve block, for infrainguinal bypass surgery, 220–221
- Fentanyl
for CABG surgery, 597–602
concentrations of, in cardiopulmonary bypass, in pediatric patients, 316–321
for congenital heart defect repair, in pediatric patients, 60–66
pKa of, at body temperature extremes, 759–762
saphenous vein effects of, 197–200
- Fibrin glue, for coronary artery fistula correction, migration of, 693–694
- Filter, vena cava, guidewire for, retrieval of, 362–363
- Fistula, coronary artery
correction of, fibrin glue migration in, 693–694
transesophageal echocardiography in, 777–780
- Fontan procedure, without cardiopulmonary bypass, 612–619
- Foramen ovale, patent. *See* Patent foramen ovale
- Foreign body, in airway, removal of, in pediatric patients, 90–92
- Fresh frozen plasma, for CABG surgery, infections and, 430–434
- Gastrointestinal system complications, in transesophageal echocardiography, 141–146
- General anesthesia, for CABG surgery
fast-track, 49–53
off-pump, 32–38
- Genetic factors, in cardiac surgical outcomes, 379–391
atrial fibrillation, 384
cardiac transplantation rejection and, 386–387
functional genomics approaches to, 380–381
inflammation and, 381–382
neurocognitive dysfunction and, 384–385
polymorphisms in, 380
principles of, 379–380
sepsis and, 382–384
vascular thrombosis and, 385–386
- Glucose control
during cardiac surgery, 201–208
tight
 evidence against, 689–690
 evidence for, 684–688
- Glue, for coronary artery fistula correction, migration of, 693–694
- Grafts
aortic valve, thrombosis of, in pregnancy, 222–224
- Grafts (*Continued*)
CABG surgery
 fentanyl effects on, 197–200
 patency of, 11–18
 stellate ganglion blockade effects on, 729–733
- Guidewire, for vena cava filter, retrieval of, 362–363
- Hallucinations, visual, closed-eye, after CABG surgery, 217–219
- Halothane, myocardial calcium cycling and, 340–344
- Hanhart syndrome, intraoperative oxygen desaturation in, 546–547
- Heart
diastolic dysfunction of, in elderly persons, 228–232
transplantation of, rejection of, genetic factors in, 386–387
- Heart failure, contractility in, remifentanyl effects on, 763–767
- Heart rate
monitoring of, after cardiac surgery, methods for, 746–750
normobaric hyperoxia effects on, after CABG surgery, 173–175
- Hematology, after CABG surgery, with cardiopulmonary bypass, 19–25
- Hematoma, in thoracic epidural anesthesia, anticoagulation and, 768–771
- Hemodilution, in cardiopulmonary bypass, hemostatic factors levels and, 459–467
- Hemodynamics
in atrial fibrillation, after cardiac surgery, in elderly persons, 182–187
in CABG surgery, fentanyl combination effects on, 597–602
after cardiac surgery, measurement of, 746–750
normobaric hyperoxia effects on, after CABG surgery, 173–175
- Hemorrhage. *See* Bleeding
- Hemostasis, for thoracic aortic surgery, 453–458
- Heparin
coating cardiopulmonary bypass circuits, 608–611
preoperative, risk/benefit of, 1–3, 4–10
thrombocytopenia due to, genetic factors in, 385–386
- Hepatic venous flow measurement, before cardiac surgery, 751–758
- Hespan, coagulation effects of, 358–361
- Hextend, coagulation effects of, 358–361
- Hydrothorax, tension, from central venous catheter, 512–515
- Hydroxyethyl starch, coagulation effects of, 358–361
- Hypercoagulability, in off-pump CABG surgery, graft patency and, 11–18
- Hyperglycemia
control of, during cardiac surgery, 201–208
tight control of
 evidence against, 689–690
 evidence for, 684–688
- Hypertension, pulmonary, inhaled prostaglandins vs. nitric oxide for, 400–405
- Hyperthermia
after cardiac surgery, 423–425, 426–429
fentanyl pKa and, 759–762
- Hypokalemia, in Bartter's syndrome, cardiac surgery in, 373–376
- Hypoplastic left heart syndrome, repair of, troponin I assay in, in neonates, 620–625
- Hypothermia
fentanyl pKa and, 759–762
for thoracic aortic surgery, outcomes of, 446–452
- Hypothyroidism, atrial fibrillation in, after cardiac surgery, in elderly persons, 182–187
- Immunoglobulin(s), for sepsis, after cardiac surgery, 440–445
- Infants
cardiac surgery in, ketamine for, 329–333
cardiopulmonary bypass for, fentanyl concentrations in, 316–321
congenital heart defect repair in, phenoxybenzamine vs. sodium nitroprusside for, 54–59
pacemaker implantation in, for atrioventricular block, 212–216
selective left bronchial intubation in, 636–641

- Infections. *See also* Sepsis
 after cardiac surgery, transfusions and, 430–434
 Infectious endocarditis, surgery for, outcome of, 435–439
- Inflammation
 in cardiac surgery
 genetic factors in, 381–382
 ketamine effects on, 329–333
 in cardiopulmonary bypass, 250–251
 xenon effects on, 488–493
- Infringuinal bypass surgery, combined sciatic and femoral nerve blocks for, 220–221
- Inotropic drugs, for cardiogenic shock, 101–103
- Insulin
 for glucose control
 during cardiac surgery, 201–208
 evidence against, 689–690
 evidence for, 684–688
 for myocardial protection, in off-pump CABG surgery, 671
- Intensive care, noncardiologist echocardiography in, 155–159
- Intraatrial septum, transesophageal echocardiography in, 146–149
- Interleukin(s), in cardiac surgery
 ketamine effects on, 329–333
 polymorphisms of, 381–384, 386–387
- Intra-aortic balloon counterpulsation
 balloon rupture during, in pediatric patients, 516–519
 for cardiogenic shock, 98–99
 misplacement of, 259–260
- Intubation, endotracheal. *See* Endotracheal intubation
- Ischemia, myocardial, cardiogenic shock in, treatment of, 97–108
- Ischemic preconditioning, in off-pump CABG surgery, 671–672
- Isoflurane
 for CABG surgery
 fast-track, 49–53
 off-pump, 708–713
 for cardiopulmonary bypass, monitoring of, with bispectral index, 485–487
- Jugular vein
 internal, cannulation of, ultrasound guidance for, 310–315
 puncture of, airway obstruction in, 659–660
- Ketamine, for congenital heart defect repair, 329–333
- Ketobemidone, for postoperative pain, in CABG surgery, 306–309
- Kidney
 dysfunction of
 after cardiopulmonary bypass, 188–192
 after deep hypothermic circulatory arrest, for thoracic aortic surgery, 446–452
 fentanyl combination effects on, 597–602
- Lactated Ringer's solution, coagulation effects of, 358–361
- Laryngeal nerve injury, in mitral valve replacement, 83–85
- Lasers, in endobronchial treatment
 in bronchoscopy suite, 118–120
 in operating room, 121–122
- Length of stay
 after CABG surgery, off-pump vs. on-pump, 26–31
 after pediatric cardiac surgery, caudal anesthesia and, 734–738
- Letters to the Editor
 Arndt endobronchial balloon cuff detachment, 273–274
 bispectral index for aortic arch occlusion diagnosis, 275–276
 bleeding after off-pump vs. on-pump CABG surgery, 700–701
 cardiac arrest due to tension pneumothorax, 135–136
 cardiac surgery in factor XII deficiency, 419–420
- Letters to the Editor (*Continued*)
 coagulation studies performed on arterial catheter samples, 702–703
 coagulation system response to cardiopulmonary bypass, 701–702
 embolectomy catheter for one-lung ventilation, 270–272
 end-tidal carbon dioxide monitoring, 133–134
 fire during tracheobronchopleural fistula repair, 556–557
 glycemic control in intensive care, 416–417
 internal jugular vein cannulation in pediatric patients, 559–561
 intrathecal morphine for minimally invasive CABG surgery, 816–818
 milrinone for pulmonary hypertension, 134–135
 mitral stenosis in pregnancy, 277–278
 off-pump CABG surgery, 416
 one-lung isolation with double-balloon blocker technique, 561–562
 oximetry readings in congenital heart disease, 558–559
 phenoxybenzamine-nitroglycerin combination in, 274–275
 pneumothorax after pneumonectomy, 557–558
 pulmonary dysfunction in off-pump vs. on-pump CABG surgery, 703
 reduction of postoperative atrial fibrillation, 816
 superior vena cava cannula obstruction, 420–421
 thoracic epidural with general anesthesia, 417–419
 thoracic sympathectomy in one-lung ventilation, 704–705
 wire-guided endobronchial blocker for one-lung ventilation, 136–138
- Levosimendan
 for cardiogenic shock, 101–103
 for diastolic dysfunction, in elderly persons, 233
 inotropic effects of, 345–349
- Lipomatous hypertrophy, of atrial septum, transesophageal echocardiography in, 146–149
- Lipopolysaccharides, in cardiac surgery, polymorphisms of, 382
- Liver
 fentanyl combination effects on, 597–602
 off-pump CABG surgery effects on, 603–607
 transplantation of, pericardial tamponade during, rescue transesophageal echocardiography in, 364–366
- Liver function tests, after CABG surgery, with cardiopulmonary bypass, 19–25
- L-NAME and L-NMMA, for cardiogenic shock, 104–105
- Lobectomy
 dexmedetomidine with epidural analgesia for, 630–635
 after myocardial infarction with stenting, procedural risks in, 795–801
- Local anesthesia, with sedation, for endovascular repair, 806–809
- Lumbar epidural anesthesia, for post-thoracotomy pain, 468–474
- Lung
 dysfunction of, after cardiopulmonary bypass, 188–192
 surgery on
 dexmedetomidine with epidural analgesia for, 630–635
 after myocardial infarction with stenting, procedural risks in, 795–801
 transesophageal echocardiography of, 242–249
 transplantation of, sequential-double, pulmonary vein thrombosis after, 225–227
- Lusitropic effects, after cardiopulmonary bypass, 334–339
- Lymphangioma, mediastinal, preoperative aspiration of, 781–784
- Magnesium
 for atrial fibrillation, in CABG surgery, 723–729
 for postoperative pain, in CABG surgery, 714–718
- Mammary artery grafts, internal, for CABG surgery, stellate ganglion blockade effects on, 729–733
- Mediastinitis, after CABG surgery, transfusions and, 430–434
- Mediastinoscopy, hemorrhage during, 678–683
- Mediastinum, cystic mass in, aspiration of, before definitive surgery, 781–784
- Methylprednisolone, for cardiopulmonary bypass, 255–258

- Microalbuminuria, after cardiopulmonary bypass, 188–192
- Midazolam, for CABG surgery, 597–602
- MIDCAB (coronary artery bypass graft (CABG) surgery, minimally invasive), intrathecal morphine for, 40–43
- Milrinone, left ventricular relaxation effects of, after cardiopulmonary bypass, 334–339
- Mini-extracorporeal circulation, for atrial septal defect closure, 656–658
- Minimally invasive surgery, for congenital heart defects, 626–629
- Minimally invasive surgery CABG, intrathecal morphine for, 40–43
- Mitral valve
 - endocarditis of, transesophageal echocardiography in, 646–649
 - regurgitation of, due to cleft, 123–125
 - repair of
 - pericardial tamponade after, 775–776
 - thoracic epidural anesthesia for, anticoagulation and, 768–771
 - replacement of
 - autologous transfusions for, 589–596
 - in Sneddon syndrome, 661–664
 - vocal cord dysfunction after, 83–85
- Monophasic defibrillation, for cardiac surgery, 738–745
- Morphine
 - for CABG surgery, fast-track, 49–53, 708–713
 - for esophagectomy, 350–357
 - intrathecal, for minimally-invasive CABG surgery, 40–43, 708–713
 - for postoperative pain
 - in aortic valve surgery, 176–181
 - in CABG surgery, 708–713
 - in thoracotomy, 468–474
- Mortality
 - in CABG surgery, in elderly persons, 583–588
 - after deep hypothermic circulatory arrest, for thoracic aortic surgery, 446–452
 - in infectious endocarditis surgery, 435–439
- Moyamoya diseases, cardiopulmonary bypass in, 499–500
- Myocardial infarction
 - after CABG surgery, echocardiographic-assisted management of, 772–774
 - cardiogenic shock in, treatment of, 97–108
 - preoperative, risk for, vs. postoperative bleeding, 1–3
 - right ventricular failure in, transesophageal echocardiography in, 406–408
 - thoracotomy after, procedural risks in, 795–801
- Myocardial ischemia
 - in CABG surgery, troponin I assay in, 288–293
 - in noncardiac surgery, troponin I assay in, 577–582
 - in off-pump CABG surgery, reduction of, 667–677
 - perioperative, beta-blockers for, late outcomes and, 237–241
 - sodium hydrogen ion exchange inhibitors for, 565–569, 570–576
 - vascular surgery in, with positive stress tests, 494–498
- Myocardial perfusion scintigraphy, for risk assessment, 521
- Myocardium
 - calcium cycling patterns in, anesthesia effects on, 340–344
 - contractility of, remifentanyl effects on, 763–767
- Myxoma, atrial, infection of, septic shock in, 508–511
- Needle-guided ultrasonography, for internal jugular vein cannulation, 310–315
- Neonates
 - cardiac surgery in, troponin elevation in, 620–625
 - pacemaker implantation in, for atrioventricular block, 212–216
- Nesiritide, for cardiogenic shock, 104
- Neurologic disorders. *See also* Stroke
 - in aortic aneurysm repair, 650–653
 - in CABG surgery, off-pump, 193–196
 - in thoracic epidural anesthesia, for cardiac surgery, 44–48
- Neutrophils, in reperfusion injury, 670–671
- Nitric oxide, inhaled, for pulmonary vasodilation, 400–405
- Nitric oxide synthase inhibitors, for cardiogenic shock, 104–105
- Nitroprusside, for cardiopulmonary bypass, in pediatric patients, 54–59
- Nonsteroidal anti-inflammatory drugs, for postoperative pain, in CABG surgery, 714–718
- Norepinephrine, for cardiogenic shock, 100–101
- Off-pump CABG surgery. *See* Coronary artery bypass graft (CABG) surgery, off-pump
- One-lung ventilation
 - arterial oxygen in, with emphysema vs. normal lung function, 479–484
 - positive end-expiratory pressure effects on, 71–75
 - selective left bronchial intubation in, in pediatric patients, 636–641
- Opioids. *See also* Morphine
 - for postoperative pain
 - in aortic valve surgery, 176–181
 - in CABG surgery, 306–309, 714–718
- Outcomes
 - of cardiac surgery, postoperative pain and, 705–707
 - of infectious endocarditis surgery, 435–439
 - of thoracic aortic surgery, with deep hypothermic circulatory arrest, 446–452
 - of vascular surgery with positive preoperative stress tests, 494–498
- Oxygen
 - desaturation of, intraoperative, in Hanhart syndrome, 546–547
 - partial pressure of, in one-lung ventilation, with emphysema vs. normal lung function, 479–484
- Oxygen therapy, after CABG surgery, hemodynamic effects of, 173–175
- Oxygenation, in one-lung ventilation, positive end-expiratory pressure effects on, 71–75
- Pacemaker implantation
 - for atrioventricular block, in pediatric patients, 212–216
 - sepsis after, 505–507
 - temporary, dysfunction of, 377–378
- Pacing, after aortic cross-clamp release, 810–811
- Patent ductus arteriosus, aortic stenosis with, 785–786
- Patent foramen ovale
 - intraoperative diagnosis of, management of, 150–154
 - transesophageal echocardiography in, 146–149
- Pediatric patients
 - airway foreign body removal from, 90–92
 - cardiac surgery in
 - caudal anesthesia for, 734–738
 - ketamine for, 329–333
 - subglottic stenosis after, 367–369
 - troponin elevation in, 620–625
 - cardiopulmonary bypass for, fentanyl concentrations in, 316–321
 - congenital heart defect repair in
 - phenoxybenzamine vs. sodium nitroprusside for, 54–59
 - remifentanyl for, 60–66
 - cystic mediastinal mass in, 781–784
 - Fontan procedure for, without cardiopulmonary bypass, 612–619
 - Hanhart syndrome in, intraoperative oxygen desaturation in, 546–547
 - pacemaker implantation in, for atrioventricular block, 212–216
 - patent ductus arteriosus with aortic stenosis in, 785–786
 - Port-Access surgery in, 626–629
 - ruptured intra-aortic balloon in, 516–519
 - selective left bronchial intubation in, 636–641
 - tetralogy of Fallot repair in, with β -thalassemia major, 93–96
- Percutaneous coronary interventions, cardiopulmonary bypass for, 501–504

- Pericardial tamponade
 after cardiac surgery, electrocardiography in, 775–776
 intraoperative, in liver transplantation, rescue transesophageal echocardiography in, 364–366
- Phenoxybenzamine, for cardiopulmonary bypass, in pediatric patients, 54–59
- Phosphodiesterase inhibitors, for cardiogenic shock, 101
- Pimobendan, for diastolic dysfunction, in elderly persons, 233
- PKa, of fentanyl, at body temperature extremes, 759–762
- Plasminogen activator inhibitor-1, polymorphisms of, 385
- Platelet(s)
 dysfunction of, genetic factors in, 385
 function of, after off-pump CABG surgery, 11–18
 transfusion of, for CABG surgery, infections and, 430–434
- Platelet inhibitors, preoperative, risk/benefit of, 1–3, 4–10
- Pleura, catheter in, for postoperative analgesia, 261–262
- Pneumectomy, dexmedetomidine with epidural analgesia for, 630–635
- Pneumonia, after CABG surgery, transfusions and, 430–434
- Pneumothorax, tension, in Hanhart syndrome, 546–547
- Port-Access cardiac surgery, in pediatric patients, 626–629
- Positive end-expiratory pressure, in one-lung ventilation, 71–75
- Postoperative pain
 in aortic valve surgery, 176–181
 in CABG surgery
 acetaminophen for, 306–309
 intrathecal morphine for, 40–43, 708–713
 magnesium sulfate for, 714–718
 NSAIDs with opioids for, 714–718
 remifentanyl for, 708–713
 spinal, 49–53
 thoracic epidural anesthesia for, 32–38
 in cardiac surgery, 705–707
 in esophagectomy, 350–357
 intrapleural catheter for, 261–262
 in thoracic surgery
 acetaminophen with thoracic epidural analgesia for, 475–478
 dexmedetomidine with epidural analgesia for, 630–635
 lumbar epidural agents for, 468–474
 preemptive epidural analgesia for, 787–794
 preoperative rofecoxib for, 67–70
- Potassium channels, fentanyl effects on, 197–200
- Prilocaine, for cardiac catheterization, in pediatric patients, 642–645
- Prostaglandins, inhaled, for pulmonary vasodilation, 400–405
- Pulmonary artery catheter
 for hemodynamic measurements, after cardiac surgery, 746–750
 kinking of, in robotic surgery, 548–550
- Pulmonary artery pressure, monitoring of, after cardiac surgery, methods for, 746–750
- Pulmonary function
 after cardiopulmonary bypass, 188–192
 transesophageal echocardiography in, 242–249
- Pulmonary hypertension, inhaled prostaglandins vs. nitric oxide for, 400–405
- Pulmonary valve, atresia of, Fontan procedure for, without cardiopulmonary bypass, 612–619
- Pulmonary vein, thrombosis of, after sequential double-lung transplantation, 225–227
- Pulse contour analysis, for cardiac output monitoring, in off-pump CABG surgery, 160–164
- Radial artery grafts, for CABG surgery, stellate ganglion blockade effects on, 729–733
- Rejection, of heart transplant, genetic factors in, 386–387
- Remifentanyl
 for congenital heart defect repair, in pediatric patients, 60–66
 for fast-track CABG surgery, 49–53
 heart contractility and, 763–767
 for postoperative pain, in CABG surgery, 708–713
- Renin-angiotensin-aldosterone system
 in Bartter's syndrome, cardiac surgery in, 373–376
 in reperfusion injury, 671
- Resource utilization, in CABG surgery
 in elderly persons, 583–588
 off-pump vs. on-pump, 26–31
- Ringer's solution, coagulation effects of, 358–361
- Risk assessment, dobutamine stress echocardiography in, 520–528
- Robotic surgery, catheter sheath kinking in, 548–550
- Rofecoxib, preoperative, for postoperative thoracotomy pain, 67–70
- Saline solutions, coagulation effects of, 358–361
- Saphenous vein graft
 fentanyl effects on, 197–200
 patency of, in off-pump CABG surgery, 11–18
- Sciatic nerve block, with femoral nerve block, for infrainguinal bypass surgery, 220–221
- Scintigraphy, myocardial perfusion, for risk assessment, 521
- Sedation, with local anesthesia, for endovascular repair, 806–809
- Seizures, after aortic dissection, 654–655
- Senning/Mustard procedure plus Rastelli, outcome of, 322–328
- Sepsis
 after cardiac surgery
 genetic factors in, 382–384
 immunoglobulins for, 440–445
 in infected atrial myxoma, 508–511
 from pacemaker and tricuspid valve endocarditis, 505–507
- Shock
 cardiogenic
 after CABG surgery, echocardiographic-assisted management of, 772–774
 perioperative treatment of, 97–108
 septic, in infected atrial myxoma, 508–511
- Shunt
 with atrial septal aneurysm, transesophageal echocardiography in, 529–538
 left-to-right, repair of, remifentanyl for, 60–66
- Sneddon syndrome, mitral valve replacement in, 661–664
- Sodium hydrogen ion exchange inhibitors
 for cardioprotection, 565–569, 570–576
 for myocardial protection, in off-pump CABG surgery, 671
- SonoHeart, evaluation of, 155–159
- Spinal analgesia, for CABG surgery, 49–53
- Staphylococcus*, in infective endocarditis, surgery for, 435–439
- Statins, for cognitive dysfunction, after cardiopulmonary bypass, 294–298
- Stellate ganglion block, effects on arterial grafts, 729–733
- Stents, in coronary artery disease
 with carotid angioplasty, for stroke prevention, 539–541
 thoracic surgery after, procedural risks in, 795–801
- Stiff person syndrome, cardiac surgery in, 370–372
- Stomach, injury of, in transesophageal echocardiography, 141–146
- Streptococcus*, in infective endocarditis, surgery for, 435–439
- Stress echocardiography, dobutamine, in risk assessment, 520–528
- Stress test, preoperative, vascular surgery after, results of, 494–498
- Stroke
 in aortic aneurysm repair, 650–653
 after CABG surgery, off-pump, 193–196
 after deep hypothermic circulatory arrest, for thoracic aortic surgery, 446–452

- Stroke (*Continued*)
 postoperative, anticoagulation and, 768–771
 prevention of, in carotid artery disease
 carotid angioplasty and stenting for, 539–541
 endarterectomy for, 542–545
- Stroke index, normobaric hyperoxia effects on, after CABG surgery, 173–175
- Subarachnoid hemorrhage, in aortic aneurysm repair, 650–653
- Subclavian artery, right, aberrant, dysphagia lusoria due to, 86–89
- Subglottic stenosis, after congenital heart defect repair, 367–369
- Sympathetic nervous system, dysfunction of, after aortic dissection, 654–655
- Systemic inflammatory response syndrome
 in cardiac surgery
 genetic factors in, 382
 ketamine effects on, 329–333
 cardiogenic shock and, 98
 after cardiopulmonary bypass, capillary leak and, 188–192
- Systemic right ventricle, correction of, outcome of, 322–328
- Systemic vascular resistance, normobaric hyperoxia effects on, after CABG surgery, 173–175
- Temperature, vs. fentanyl pKa, 759–762
- Tension hydrothorax, from central venous catheter, 512–515
- Tension pneumothorax, in Hanhart syndrome, 546–547
- Tetralogy of Fallot, repair of, with β -thalassemia major, 93–96
- Tezosentan, for cardiogenic shock, 103–104
- β -Thalassemia major, tetralogy of Fallot repair in, 93–96
- Thermodilution
 for cardiac output monitoring, in off-pump CABG surgery, 160–164
 for hemodynamic measurements, after cardiac surgery, 746–750
- Thoracic epidural anesthesia
 for aortic valve surgery, extubation after, 176–181
 for CABG surgery, off-pump, 32–38
 for cardiac surgery
 with cardiopulmonary bypass, 300–305
 prospective audit of, 44–48
 for esophagectomy, 350–357
 for mitral valve surgery, anticoagulation and, 768–771
 for thoracotomy, 630–635
 acetaminophen with, 475–478
 for postoperative pain, 787–794
- Thoracotomy
 after myocardial infarction with stenting, procedural risks in, 795–801
 postoperative pain management in
 acetaminophen with thoracic epidural analgesia for, 475–478
 lumbar epidural agents for, 468–474
 preemptive epidural analgesia for, 787–794
 preoperative rofecoxib for, 67–70
- Thrombocytopenia, heparin-induced, genetic factors in, 385–386
- Thromboelastography, volume expander effects on, 358–361
- Thromboembolism, in thoracic epidural anesthesia, anticoagulation and, 768–771
- Thrombosis
 aortic valve graft, in pregnancy, 222–224
 in cardiac surgery, genetic factors in, 385–386
 in marantic endocarditis, in afibrinogenemia, 109–117
 pulmonary vein, after sequential double-lung transplantation, 225–227
 saphenous vein graft, in off-pump CABG surgery, 11–18
- Thyroid hormone deficiency, atrial fibrillation in, after cardiac surgery, in elderly persons, 182–187
- Thyroidectomy, subtotal, off-pump CABG surgery with, 79–82
- Toborinone, for cardiogenic shock, 101
- Topical analgesia, for chest tube removal, 719–722
- Trachea, lesions of, off-pump CABG surgery with subtotal thyroidectomy in, 79–82
- Tramadol, epidural, for post-thoracotomy pain, 468–474
- Tranexamic acid, for thoracic aortic surgery, 453–458
- Transesophageal echocardiography
 in aortic aneurysm repair, 165–172
 in atrial septal aneurysm diagnosis, 529–538
 in cardiogenic shock, after CABG surgery, 772–774
 in coronary artery fistula, 777–780
 after coronary artery fistula correction, 693–694
 in endocarditis, 646–649
 in esophageal stricture, 209–211
 gastrointestinal complications of, 141–146
 in hemodynamic monitoring, after cardiac surgery, 746–750
 in interatrial septum, 146–149
 in pacemaker infections, 505–507
 in patent foramen ovale, 150–154
 in pericardial tamponade
 after cardiac surgery, 775–776
 intraoperative, 364–366
 in preoperative hepatic venous flow measurement in, 751–758
 in pulmonary disease, 242–249
 in pulmonary vein thrombosis, after double-lung transplantation, 225–227
 in right ventricular failure, 406–408
- Transfusion(s)
 autologous, allogeneic blood transfusion reduction with, 589–596
 for CABG surgery
 heparin-bonded circuits effects on, 608–611
 infections and, 430–434
- Transgastric echocardiography, artifacts in, with papillary anomaly, 126–127
- Transplantation
 heart, rejection of, genetic factors in, 386–387
 liver, pericardial tamponade during, rescue transesophageal echocardiography in, 364–366
 lung, sequential-double, pulmonary vein thrombosis after, 225–227
- Transposition of great arteries
 arterial switch for, outcome of, 322–328
 correction of, troponin I assay in, in neonates, 620–625
- Transpulmonary thermodilution, for cardiac output monitoring, in off-pump CABG surgery, 160–164
- Tricuspid valve
 atresia of, Fontan procedure for, without cardiopulmonary bypass, 612–619
 endocarditis of, with pacemaker infection, 505–507
- Triiodothyronine, deficiency of, atrial fibrillation in, after cardiac surgery, in elderly persons, 182–187
- Troponin I assay
 in cardiac surgery, in neonates, 620–625
 in myocardial ischemia
 after CABG surgery, 288–293
 in noncardiac surgery, 577–582
- Tube, chest, removal of, topical analgesia for, 719–722
- Tumor necrosis factor(s), in cardiac surgery, polymorphisms of, 381–384
- Ultrasonography, for internal jugular vein cannulation, 310–315
- Urinary tract infections, after CABG surgery, transfusions and, 430–434
- Valdecoxib, topical, for chest tube removal, 719–722
- Valvular heart disease. *See also specific valves*
 prosthetic valves for, intra-annular leak of, 691–692
 surgery for
 autologous transfusions for, 589–596


Valvular heart disease. *See also specific valves (Continued)*
 sepsis after, immunoglobulins for, 440-445
 in stiff person syndrome, 370-372
 vocal cord dysfunction after, 83-85
 Vascular stent procedures, anesthesiologist needed for
 evidence against, 806-809
 evidence for, 802-805
 Vascular surgery, noncardiac
 with positive preoperative stress tests, results of, 494-498
 troponin screening in, 577-582
 zoniopride for, 570-576
 Vasoconstrictors, for cardiogenic shock, 104-105
 Vasodilators
 for cardiogenic shock, 103-104
 fentanyl as, in CABG surgery, 197-200
 pulmonary, inhaled prostaglandins vs. nitric oxide, 400-405
 Vena cava filter, guidewire for, retrieval of, 362-363
 Venous grafts, patency of, in off-pump CABG surgery, 11-18
 Ventilation, one-lung
 arterial oxygen in, with emphysema vs. normal lung function, 479-484
 positive end-expiratory pressure effects on, 71-75
 selective left bronchial intubation in, 636-641

Ventricle(s)
 left
 air in, transesophageal echocardiography in, 406-408
 relaxation of, after cardiopulmonary bypass, 334-339
 right
 failure of, transesophageal echocardiography in, 406-408
 systemic, repair of, 322-328
 Ventricular assist devices
 aortic regurgitation after, 409-410
 intraoperative off-bypass management of, 76-78
 Ventricular fibrillation, in cardiac surgery, defibrillation methods for,
 738-745
 Ventricular muscle, contractility of, remifentanyl effects on, 763-767
 Visual hallucinations, closed-eye, after CABG surgery, 217-219
 Vocal cord dysfunction, after mitral valve replacement, 83-85
 Volume expanders, coagulation effects of, 358-361
 Wound infections, after CABG surgery, transfusions and, 430-
 434
 Xenon, in inflammatory response, in cardiopulmonary bypass, 488-
 493
 Zoniopride, for cardioprotection, 570-576

United States Postal Service

Statement of Ownership, Management, and Circulation

1. Publication Title		2. Publication Number		3. Filing Date	
Journal of Cardiothoracic and Vascular Anesthesia		1 0 5 3 - 0 7 7 0		9/15/05	
4. Issue Frequency		5. Number of Issues Published Annually		6. Annual Subscription Price	
Feb, Apr, Jun, Aug, Oct, Dec		6		\$283.00	
7. Complete Mailing Address of Known Office of Publication (Not printer) (Street, city, county, state, and ZIP+4)				Contact Person	
Elsevier Inc., 6277 Sea Harbor Drive Orlando, FL 32887-4900				Stephen Bushing Telephone 215-239-3688	
8. Complete Mailing Address of Headquarters or General Business Office of Publisher (Not printer)					
Elsevier Inc., 360 Park Avenue South, New York, NY 10010-1710					
9. Full Names and Complete Mailing Addresses of Publisher, Editor, and Managing Editor (Do not leave blank)					
Publisher (Name and complete mailing address)					
David Dionne, Elsevier Inc., 360 Park Avenue South, New York, NY 10010-1710 Editor (Name and complete mailing address)					
Joel A. Kaplan, MD, Emeritus Dean School of Medicine, Professor of Anesthesiology, University of Louisville, Abell Administration Center, 323 East Chestnut St., Louisville, KY 40202-3866 Managing Editor (Name and complete mailing address)					
Daniel W. Alkofer, Ph.D., 323 E. Chestnut Street, Louisville, KY 40202					
10. Owner (Do not leave blank. If the publication is owned by a corporation, give the name and address of the corporation immediately followed by the names and addresses of all stockholders owning or holding 1 percent or more of the total amount of stock. If not owned by a corporation, give the names and addresses of the individual owners. If owned by a partnership or other unincorporated firm, give its name and address as well as those of each individual owner. If the publication is published by a nonprofit organization, give its name and address.)					
Full Name		Complete Mailing Address			
Wholly owned subsidiary of		4520 East-West Highway			
Reed/Elsevier, US holdings		Bethesda, MD 20814			
11. Known Bondholders, Mortgagees, and Other Security Holders Owning or Holding 1 Percent or More of Total Amount of Bonds, Mortgages, or Other Securities. If none, check box					
None		None			
Full Name		Complete Mailing Address			
N/A					

13. Publication Title		14. Issue Date for Circulation Data Below	
Journal of Cardiothoracic and Vascular Anesthesia		August 2005	
15. Extent and Nature of Circulation		Average No. Copies Each Issue During Preceding 12 Months	No. Copies of Single Issue Published Nearest to Filing Date
a. Total Number of Copies (Net press run)		2708	3700
b. Paid and/or Requested Circulation	(1) Paid/Requested Outside-County Mail Subscriptions Stated on Form 3541. (Include advertiser's proof and exchange copies)	988	928
	(2) Paid In-County Subscriptions Stated on Form 3541 (Include advertiser's proof and exchange copies)		
	(3) Sales Through Dealers and Carriers, Street Vendors, Counter Sales, and Other Non-USPS Paid Distribution	544	531
	(4) Other Classes Mailed Through the USPS		
c. Total Paid and/or Requested Circulation (Sum of 15b. (1), (2), (3), and (4))		1532	1459
d. Free Distribution by Mail (Samples, complimentary, and other free)	(1) Outside-County as Stated on Form 3541	367	372
	(2) In-County as Stated on Form 3541		
	(3) Other Classes Mailed Through the USPS		
e. Free Distribution Outside the Mail (Carriers or other means)			
f. Total Free Distribution (Sum of 15d. and 15e.)		367	372
g. Total Distribution (Sum of 15c. and 15f.)		1899	1831
h. Copies not Distributed		809	1869
i. Total (Sum of 15g. and h.)		2708	3700
j. Percent Paid and/or Requested Circulation (15c. divided by 15g. times 100)		81%	80%
16. Publication of Statement of Ownership			
Publication required. Will be printed in the December 2005 issue of this publication.		Publication not required	
17. Signature and Title of Editor, Publisher, Business Manager, or Owner		Date	
 Jean M. Fanucci, Executive Director of Subscription Services		9/15/05	
I certify that all information furnished on this form is true and complete. I understand that anyone who furnishes false or misleading information on this form or who omits material or information requested on the form may be subject to criminal sanctions (including fines and imprisonment) and/or civil sanctions (including civil penalties).			

12. Tax Status (For completion by nonprofit organizations authorized to mail at nonprofit rates) (Check one)
 The purpose, function, and nonprofit status of this organization and the exempt status for federal income tax purposes:
 Has Not Changed During Preceding 12 Months
 Has Changed During Preceding 12 Months (Publisher must submit explanation of change with this statement)
 (See Instructions on Reverse)